Antihypertensive efficacy of amlodipine in patients with arterial hypertension taking omeprazole depending on genetic polymorphism of patients

Dorofeeva M.N.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

Shikh E.V.

Kafedra klinicheskoĭ farmakologii i propedevtiki vnutrennikh bolezneĭ GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova"

Sizova Zh.M.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Denicenko N.P.

Russian Medical Academy of Continuous Professional of Healthcare Ministry of the Russia, Moscow, Russia

Ryzhikova K.A.

Russian Medical Academy of Continuous Professional of Healthcare Ministry of the Russia, Moscow, Russia

Lapidus N.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

Ismagilov A.D.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

Antihypertensive efficacy of amlodipine in patients with arterial hypertension taking omeprazole depending on genetic polymorphism of patients

Authors:

Dorofeeva M.N., Shikh E.V., Sizova Zh.M., Sychev D.A., Denicenko N.P., Ryzhikova K.A., Lapidus N.I., Ismagilov A.D.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2018;11(2): 45‑50

DOI: 10.17116/kardio201811245-50

Downloaded: 18

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Dorofeeva MN, Shikh EV, Sizova ZhM, et al. . Antihypertensive efficacy of amlodipine in patients with arterial hypertension taking omeprazole depending on genetic polymorphism of patients. Russian Journal of Cardiology and Cardiovascular Surgery. 2018;11(2):45‑50. (In Russ.)
https://doi.org/10.17116/kardio201811245-50

Подписка 2025-2 (Russian Journal of Cardiology and Cardiovascular Surgery)

Close metadata

Recommended articles:

Arterial hypertension in patients — military fighting participants. Russian Journal of Preventive Medicine. 2024;(5):128-132

The problem of diabetes mellitus in obstetrics. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):25-29

Physical methods of correction of arterial hypertension: modern concepts. (A literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(3):41-47

Impact of metabolic parameters and risk factors on surfactant proteins SP-A and SP-D in abdominal obesity. Russian Journal of Preventive Medicine. 2024;(7):60-66

Features of cognitive impairment in bipolar affective disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64

Features of autonomic regulation of heart rate variability in young people at the cardiovascular pathology prevention. Russian Journal of Preventive Medicine. 2024;(8):76-81

Assessment of lipid and carbohydrate metabolism in the population of South Yakutia by the effective radiation dose level. Russian Journal of Preventive Medicine. 2024;(8):82-86

Forensic characteristic of sudden death cases in subjects with metabolic syndrome. Forensic Medical Expertise. 2024;(4):54-57

Aim — to analyze antihypertensive efficacy of amlodipine in patients with arterial hypertension (AH) combined with acid-related diseases taking omeprazole. Material and methods. Pharmacotherapy and pharmacodynamic efficacy of amlodipine were evaluated in 51 patients with AH and acid-related diseases. Results. Certain genetic polymorphism of CYP2C19P450 isoenzyme is followed by omeprazole metabolism shift to CYP3A4P450, that is confirmed by significant inhibition of CYP3A4P450 activity on background of combined therapy omeprazole + amlodipine in patients with slow metabolism compared with fast and intermediate metabolization. Decreased activity of CYP3A4P450 in patients with slow metabolization leads to slower metabolism of amlodipine followed by increased concentration in blood plasma and more pronounced antihypertensive effect. Conclusion. CYP2C19P450 gene polymorphism determines not only therapeutic effect of various proton pump inhibitors as described in the literature but also antihypertensive effect of amlodipine.

Keywords:

amlodipine

omeprazole

correlation

metabolism

CYP2С19

CYP3А4

arterial hypertension

acid-related disease

co-morbidity

Authors:

Dorofeeva M.N.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

Shikh E.V.

Kafedra klinicheskoĭ farmakologii i propedevtiki vnutrennikh bolezneĭ GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova"

Sizova Zh.M.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Denicenko N.P.

Russian Medical Academy of Continuous Professional of Healthcare Ministry of the Russia, Moscow, Russia

Ryzhikova K.A.

Russian Medical Academy of Continuous Professional of Healthcare Ministry of the Russia, Moscow, Russia

Lapidus N.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

Ismagilov A.D.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russia, Moscow, Russia

List of references:

Khlynova OV, Tuev AV, Beresneva LN, Agafonov AV. Problema komorbidnosti s uchetom sostoyaniya serdecno-sosydistoi sistemy u patients s arterialnoi gipertenziey i kislotozavisimymi zabolevaniyami. Kazan med journal. 2013;94:1:80-85. (In Russ.)
Sychev DA, Sosnovskiy EE, Orechov RE, Bordovskiy SG. Polipragmaziya v klinicheskoi practike. Saint-Petersburg. 2016. (In Russ.)
Kukes VG, Grachev SV, Sychev DA, Ramenskaya GV. Metabolism lekarstvennych sredstv. Nauchnye osnovy perconalizirovannoi meditciny. 2008. (In Russ.)
Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2 D6, CYP2 C19, CYP3 As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004;19:83-95.
Sychev DA, Muslimova OV, Garrisyuk EV, Kosovskaya AV, Kukes VG. Farmakogereticheskiye texnologii personalizirovnnoi meditciny: optimizaciya prmeneniya lekastvennykh sredstv. Terra Medica. 2011;1:4-9. (In Russ.)
Klinicheskaya farmakologiya: uchebnik. Pod red. Kukes VG. 4-e, perer. i dop. M.: GEOTAR-Mediya, 2008;229-230. (In Russ.)
Shikh EV, Sychev DA. Bezopasnost’ pantoprozola s pozicii lekarstevnnogo vzaimodeistviya. Russ J Gastroenterology, gepatology i kolonoproktologii. 2012;22:5:4-12. (In Russ.)
Morozova TE, Sychev DA, Shikh NV. Farmakogeneticheskie podkhody k prognozirovaniyu effectivnosti i bezopastnosti amlodopina u bolnykh arterial’noi gipertenziyei. Lechaschii vrach. 2016;3:77-82. (In Russ.)
Kukes VG, Sychev DA, Shikh EV. Izucheniye biotransformacii lekarstvennykh sredstv — put’ k povyscheniyu effectivnosti i bezopastnosti farmakoterapii. Vrach. 2007;1:23-27. (In Russ.).
Shevchenko OV, Bychkov RN, Posnenkova OM, Dovgalevskiy PYa, Bogoslovskaya SI, Svistunov AA. Znacheniye farmakogeneticheskih issledovanii dlya optimizacii antigipertenzivnoy terapii. 2012;3:95-100. (In Russ.)
Morozova TE, Cychev DA, Shich NV. Klinico-farmakologicheskie aspekty izycheniya stepeni associacii mejdy farmakokineticheskimi parametrami, klinicheskoi effectivnost’yu amlodipina i geneticheskimi osobennostyami patientov s AG I—II stadii. Biomeditsina. 2016;4:12-16. (In Russ.)

Close metadata